Lab-Grown tumor clones could guide chemo choices for bone cancer

NCT ID NCT06064682

Recruiting now Knowledge-focused Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether growing a patient's osteosarcoma cells in the lab (as organoids) can predict which chemotherapy drugs will work best. Researchers will take tissue from routine biopsies or surgeries of 40 people with suspected or confirmed osteosarcoma. The goal is to see if this approach is feasible and if drug sensitivity in the lab matches the tumor's response in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a lab test that helps doctors choose the most effective chemotherapy for each osteosarcoma patient.
What could go wrong: This is a small, early feasibility study (40 participants) focused on lab testing, not treatment. It may not show that organoid predictions improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOSARCOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.